CCL2 is overexpressed at tumor sites, malignant pleural effusions, and sera of breast cancer patients, and its increased levels in the tumor microenvironment and circulation were associated with disease progression, early relapse, tumor grade and aggressiveness, and poor prognosis [99]. This evidence concerns the gene CCL2 and breast cancer.